Advancing Repurposed Therapeutics for Epidermolysis Bullosa (ART-EB)
Research area:
Rare disease
Disease:
Intervention:
Phase:
Related news
TYSABRI gains market approval
Keytruda receives another breakthrough designation
Research area:
Disease:
Intervention:
Phase: